MAKO Surgical (NASDAQ: MAKO) was upgraded by equities research analysts at Summer Street from a “neutral” rating to a “buy” rating in a research note issued to investors on Tuesday.
Separately, analysts at JPMorgan Chase & Co. (NYSE: JPM) cut their price target on shares of MAKO Surgical to $32.00 in a research note to investors on Tuesday, December 20th. They now have a “neutral” rating on the stock. Analysts at Goldman Sachs (NYSE: GS) reiterated a “buy” rating on shares of MAKO Surgical in a research note to investors on Thursday, November 10th. Also, analysts at Canaccord Genuity raised their price target on shares of MAKO Surgical from $24.50 to $30.00 in a research note to investors on Thursday, November 10th. They now have a “hold” rating on the stock.
MAKO Surgical Corp. (MAKO) is a medical device company that markets its advanced robotic arm solution and orthopedic implants for minimally invasive orthopedic knee procedures. The Company offers MAKOplasty, a restorative surgical solution that enables orthopedic surgeons to treat patient-specific, early to mid-stage osteoarthritic knee disease. MAKOplasty is performed using the Company’s RIO Robotic Arm Interactive Orthopedic system (RIO), and its RESTORIS unicompartmental and RESTORIS MCK multi-compartmental knee implant systems. The RIO utilizes tactile guided robotic arm technology and patient-specific visualization to prepare the knee joint for the insertion and alignment of the Company’s resurfacing implants through a small incision in a minimally invasive, bone preserving and tissue sparing procedure. The Company’s RESTORIS family of knee implants is designed to enable minimally invasive restoration of one or two of the diseased compartments of the knee joint.
Shares of MAKO Surgical traded up 10.21% during mid-day trading on Tuesday, hitting $27.785. MAKO Surgical has a 52 week low of $14.04 and a 52 week high of $43.00. The stock’s 50-day moving average is $28.03 and its 200-day moving average is $32.15. The company has a market cap of $1.157 billion.
Stay on top of analysts’ coverage with our daily email newsletter that provides a concise list of analysts’ upgrades, analysts’ downgrades and analysts’ price target changes for each day. Click here to register